To mechanistically confirm that SREBPs inhibition contributes to the anti-myeloma effects of SEL, we performed shRNA-mediated knockdown of SREBF1 and SREBF2 in MM cells, with knockdown efficiency confirmed by immunoblotting (Fig. 3f). Here, SREBF1 is linked to Miyoshi myopathy.